Cyclacel Pharmaceuticals Stock News

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2021 Results - Earnings Call Transcript

-Initial Data from Phase 1/2 Study of Oral Fadraciclib in Solid Tumors Expected in First Half of 2022 –

BERKELEY HEIGHTS, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that management will be presenting at the virtual 32 nd Annual Oppenheimer Healthcare Conference and participating in the Targeted Oncology Panel as part of the Conference.

BERKELEY HEIGHTS, N.J., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative

BERKELEY HEIGHTS, N.J., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will participate in the Biotech Showcase 2022 Virtual Conference to be held January 10-12, 2022. Spiro Rombotis, President & Chief Executive Officer, will present an overview of Cyclacels business and the Company will be available for virtual meetings during the conference. In addition, Mr. Rombotis will participate in a Biotech Showcase Workshop, entitled , Outsmarting Cancer: Next Generation Therapies.

Geode Capital Management LLC increased its holdings in shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) by 143.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,860 shares of the biotechnology companys stock after buying an additional 29,956 shares during the []

Wall Street brokerages expect that Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) will report earnings per share of ($0.66) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Cyclacel Pharmaceuticals earnings, with the lowest EPS estimate coming in at ($0.71) and the highest estimate coming in at ($0.63). Cyclacel Pharmaceuticals posted earnings per []

Cyclacel Pharmaceuticals (NASDAQ:CYCC) had its price objective dropped by research analysts at LADENBURG THALM/SH SH from $18.00 to $17.00 in a research note issued to investors on Thursday, The Fly reports. The firm presently has a buy rating on the biotechnology companys stock. LADENBURG THALM/SH SHs price objective would suggest a potential upside of 264.03% []

Boothbay Fund Management LLC decreased its holdings in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) by 66.7% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,545 shares of the biotechnology companys stock after selling 21,089 shares during the period. Boothbay Fund Management LLC owned approximately 0.11% of Cyclacel []

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q3 2021 Results - Earnings Call Transcript

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2021 Results - Earnings Call Transcript

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2021 Results - Earnings Call Transcript

BERKELEY HEIGHTS, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative

Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) priced an underwritten public offering of 1.81 million common shares at $7 per share, a discount of 11% on the last close price of $7.87 on Thursday. It